- Home
- PMM vs PRQR Comparison
PMM vs PRQR Comparison
Compare PMM & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- PRQR
- Stock Information
- Founded
- PMM 1989
- PRQR 2012
- Country
- PMM United States
- PRQR Netherlands
- Employees
- PMM N/A
- PRQR N/A
- Industry
- PMM Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- PRQR Health Care
- Exchange
- PMM Nasdaq
- PRQR Nasdaq
- Market Cap
- PMM 296.6M
- PRQR 309.5M
- IPO Year
- PMM N/A
- PRQR 2014
- Fundamental
- Price
- PMM $6.35
- PRQR $3.56
- Analyst Decision
- PMM
- PRQR Strong Buy
- Analyst Count
- PMM 0
- PRQR 4
- Target Price
- PMM N/A
- PRQR $7.13
- AVG Volume (30 Days)
- PMM 118.3K
- PRQR 531.5K
- Earning Date
- PMM 01-01-0001
- PRQR 11-07-2024
- Dividend Yield
- PMM 4.68%
- PRQR N/A
- EPS Growth
- PMM N/A
- PRQR N/A
- EPS
- PMM 0.23
- PRQR N/A
- Revenue
- PMM N/A
- PRQR $20,506,357.00
- Revenue This Year
- PMM N/A
- PRQR $370.31
- Revenue Next Year
- PMM N/A
- PRQR N/A
- P/E Ratio
- PMM $26.52
- PRQR N/A
- Revenue Growth
- PMM N/A
- PRQR 306.68
- 52 Week Low
- PMM $5.00
- PRQR $1.61
- 52 Week High
- PMM $6.42
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PMM 54.83
- PRQR 50.61
- Support Level
- PMM $6.34
- PRQR $3.37
- Resistance Level
- PMM $6.42
- PRQR $3.67
- Average True Range (ATR)
- PMM 0.07
- PRQR 0.19
- MACD
- PMM 0.02
- PRQR -0.06
- Stochastic Oscillator
- PMM 64.52
- PRQR 31.67
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.